Asianet Newsable on MSN
mRNA stock rallies over 40% in June: Moderna bets its future on cancer, autoimmune disease and AI-powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes ...
MarketBeat on MSN
Short Squeeze Alert-Moderna Stock Surges on New Strategy
Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...
The company's pending vaccine approvals could help the stock continue its rise.
Provides broad overview of Company's research and early development programs expected to continue to fuel future ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...
The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results